Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Soleno Therapeutics Inc (SLNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SLNO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $117
1 Year Target Price $117
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 215.96% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.11B USD | Price to earnings Ratio - | 1Y Target Price 117 |
Price to earnings Ratio - | 1Y Target Price 117 | ||
Volume (30-day avg) 8 | Beta -2.56 | 52 Weeks Range 41.50 - 90.32 | Updated Date 08/15/2025 |
52 Weeks Range 41.50 - 90.32 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.22 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.64 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) -16.61% |
Management Effectiveness
Return on Assets (TTM) -36.6% | Return on Equity (TTM) -69.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3877225896 | Price to Sales(TTM) 125.89 |
Enterprise Value 3877225896 | Price to Sales(TTM) 125.89 | ||
Enterprise Value to Revenue 118.73 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 53145000 | Shares Floating 43553929 |
Shares Outstanding 53145000 | Shares Floating 43553929 | ||
Percent Insiders 1.79 | Percent Institutions 111.75 |
Upturn AI SWOT
Soleno Therapeutics Inc
Company Overview
History and Background
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of rare diseases. Founded in 2011, Soleno's primary focus is on Prader-Willi Syndrome (PWS).
Core Business Areas
- Pharmaceutical Development: Focuses on the development and commercialization of Diazoxide Choline Controlled Release (DCCR) for the treatment of Prader-Willi Syndrome.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure includes research, development, and commercialization departments.
Top Products and Market Share
Key Offerings
- DCCR (Diazoxide Choline Controlled Release): DCCR is Soleno's lead product candidate being developed for the treatment of Prader-Willi Syndrome (PWS). Currently awaiting FDA approval after facing initial rejection. There is no available market share data yet as the drug has not been approved. Competitors are mainly off-label treatments and supportive care.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant investment in research and development. Orphan drug designation provides market exclusivity and other incentives for companies developing treatments for rare diseases.
Positioning
Soleno is positioned as a company specializing in treatments for rare diseases, specifically PWS. The company aims to address the unmet medical needs of PWS patients. Its success depends on the approval of DCCR by the FDA.
Total Addressable Market (TAM)
The estimated total addressable market for PWS treatments is substantial, considering the lack of approved therapies. The TAM size depends on the pricing of future drug and the potential market penetration. Soleno is well-positioned to capture a significant portion of this TAM if DCCR gains approval.
Upturn SWOT Analysis
Strengths
- Focus on a rare disease with unmet medical needs
- Lead product candidate (DCCR) with promising clinical trial results
- Orphan drug designation offering market exclusivity
Weaknesses
- Dependence on a single product candidate
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory risks associated with FDA approval
Opportunities
- Potential FDA approval of DCCR
- Expansion to other indications beyond PWS
- Partnerships or collaborations with larger pharmaceutical companies
Threats
- Regulatory setbacks or rejection of DCCR
- Competition from other companies developing PWS treatments
- Changes in reimbursement policies or pricing pressures
Competitors and Market Share
Key Competitors
- CPRX
- ZGNX
- TEVA
- NEON
Competitive Landscape
Solenou2019s competitive advantages depend on DCCR's efficacy, safety, and market exclusivity. Its disadvantages include dependence on a single product and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by clinical trial progress and fundraising activities.
Future Projections: Future growth is heavily reliant on the FDA approval of DCCR. Analyst estimates depend on approval and market penetration.
Recent Initiatives: Recent initiatives include continued clinical development of DCCR and regulatory submissions to the FDA.
Summary
Soleno Therapeutics is a clinical-stage company with a focus on Prader-Willi Syndrome. Its future hinges on FDA approval of DCCR, which could lead to substantial growth. The company faces regulatory risks and competition, but successful commercialization could significantly improve the lives of PWS patients. The company needs to seek and secure more funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- FDA
Disclaimers:
The analysis is based on publicly available information and analyst estimates, and should not be considered financial advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Soleno Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-13 | Chairman, President, CEO & COO Dr. Anish Bhatnagar M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://soleno.life |
Full time employees 133 | Website https://soleno.life | ||
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.